On December 29, 2022, the grand ceremony of the “Top 50 Innovative Biotechnology Companies in Guangdong-Hong Kong-Macao Greater Bay Area Award 2022” took place in Nansha, Guangzhou. Shenzhen Eureka Biotechnology Co., Ltd. (hereinafter referred to as “EurekaBio”) received the prestigious “Top 50 Innovative Biotechnology Enterprises in Guangdong-Hong Kong-Macao Greater Bay Area - Pioneer Enterprise Award”. This esteemed recognition was a testament to EurekaBio's leading-edge innovation capabilities, substantial research and development prowess, and promising trajectory of growth. 

The selection of the top 50 innovative biotechnology companies in the Greater Bay Area encompassed three pivotal domains: medical devices, biopharmaceuticals and technologies, and medical services. Through a comprehensive evaluation of participating companies' technological innovation, market application, and capital aspects, the selection aims to assess their innovation capabilities and future development prospects. As a result, a diverse range of accolades including the "Leading Enterprise Award", "Pioneer Enterprise Award", "Emerging Enterprise Award" and "Best Popularity Award" were presented to outstanding companies. This initiative aims to identify future unicorns in the biotechnology sector within the Greater Bay Area, foster an integrated innovation ecosystem involving academia, industry, and research institutions, promote the deep integration and development of biotechnology in Guangdong, Hong Kong, and Macao, and drive the overall growth of the biotechnology industry.
In recent years, the Guangdong-Hong Kong-Macau Greater Bay Area has emerged as a crucial hub for China's biopharmaceutical industry. This area has witnessed the flourishing growth of biopharmaceutical enterprises. EurekaBio, as a company deeply rooted in the region, is committed to researching and developing key technologies and processes in the field of CGT. On one hand, EurekaBio has independently developed and introduced the CellSep® series cell processing systems as well as sterile tube welders, heat sealers, CytoLinX WB single-use rocking bioreactors, and other essential equipment for the production of cell therapy products, effectively reducing costs and enhancing efficiency in the CGT industry. On the other hand, EurekaBio has successfully overcome global technological challenges in the production of lentiviral vectors in the CGT field. Through the innovative development of the EuLV® system, which is based on stable cell producer lines, the company has enabled large-scale production of lentiviral vectors. This breakthrough achievement has positioned China as a leader in the global CGT industry. The acknowledgment of EurekaBio with the “Pioneer Enterprise Award” signifies the recognition and endorsement it has received from various stakeholders. This prestigious accolade highlights EurekaBio's technical excellence, innovative approach, commercial viability, and promising prospects in the market. 

In the future, EurekaBio will steadfastly embrace its role as a torchbearer, tenaciously preserving its ethos of meticulousness and boundless ingenuity. Through adherence to scientific rigor and the relentless pursuit of cutting-edge breakthroughs, EurekaBio will endeavor to realize greater accessibility to CGT products and medications, thereby driving the development of the CGT industry.